Clinical Scorecard: The Role of Circular RNA circEVI5 as a miR-433 Inhibitor in Enhancing Oncogenic Signaling through GBP2 in Renal Cell Carcinoma Progression
At a Glance
Category
Detail
Condition
Renal Cell Carcinoma
Key Mechanisms
circEVI5 acts as a sponge for miR-433, promoting GBP2 expression and oncogenic signaling.
Target Population
Patients with Renal Cell Carcinoma
Care Setting
Oncology
Key Highlights
CircEVI5 is significantly upregulated in RCC tissues and cell lines.
High circEVI5 expression correlates with advanced tumor stage and poor survival.
CircEVI5 promotes RCC cell proliferation, migration, and invasion.
GBP2 overexpression in RCC tissues predicts reduced survival.
miR-433 levels are inversely correlated with circEVI5 and GBP2.
Guideline-Based Recommendations
Diagnosis
Utilize TCGA datasets for expression profiling of circEVI5.
Management
Consider targeting the circEVI5/miR-433/GBP2 axis for therapeutic interventions.
Monitoring & Follow-up
Monitor circEVI5 and miR-433 levels as potential prognostic biomarkers.
Risks
High circEVI5 expression may indicate a higher risk of poor prognosis in RCC patients.
Patient & Prescribing Data
Patients diagnosed with Renal Cell Carcinoma.
Targeting circEVI5 may enhance therapeutic strategies against RCC.
Clinical Best Practices
Incorporate circEVI5 expression analysis in RCC patient evaluations.
Evaluate the potential of RNA-based therapies targeting circEVI5.
